Moderna2026-10-10 22:44:59Moderna tops S&P 500 in 2026 with gains of more than 600%Moderna, not an AI-linked chipmaker, has become the best-performing stock in the S&P 500 so far in 2026, according to Techub, citing BeInCrypto. The vaccine maker’s shares have climbed more than 600% this year and closed at $225 last Friday. The rally was tied to late-stage trial results for its experimental cancer vaccine. The surge also pushed Moderna back into the Nasdaq-100 Index. More than 200 funds tracking that benchmark, with over $800 billion in assets under management, are required to buy the stock. Moderna and Merck said on Aug. 19 that their experimental cancer vaccine passed a final-stage trial in melanoma patients, though detailed results have not yet been released. Investors are expected to get the full trial data on Oct. 24 at a major cancer conference in Madrid. Not everyone is convinced the move can hold. Former pharmaceutical executive Martin Shkreli said Moderna’s stock bubble could burst within the next six months.140
cancer vaccin2026-09-08 02:20:09Tempus AI Could See Over $600M in Annual Revenue from Cancer Vaccine Sequencing, Analysts SayModerna and Merck's personalized cancer vaccines have added over $50 billion in market value to the two drugmakers. The diagnostic sequencing process behind these vaccines is emerging as a new investment opportunity. Tempus AI, as a sequencing partner for the Moderna-Merck vaccine, could benefit if the vaccine is approved. Piper Sandler estimates the melanoma vaccine alone could generate at least $50 million in annual sequencing revenue, while BTIG analyst Mark Massaro projects the figure could exceed $600 million. The post-treatment cancer recurrence monitoring market via blood tests is seen as a multi-billion-dollar opportunity, but Natera currently dominates. However, uncertainties remain in the mRNA cancer vaccine field, and pharma companies may internalize some sequencing work in the future.1110
Moderna2026-08-20 02:56:58Moderna shares jump 176.97% after melanoma vaccine trial success with MerckModerna and Merck said their jointly developed mRNA melanoma vaccine trial met its goal, setting off a sharp rally in biopharma stocks. Moderna shares surged as much as 176.97% on Wednesday and closed at $174, marking the company’s biggest single-day gain on record, according to ABMedia. Merck also rose more than 12.60% to $152.20. The report said the vaccine candidate, Intismeran Autogene, used in combination with Merck’s Keytruda, reduced the risk of recurrence for some melanoma patients. Leerink Partners analyst Daina Graybosch called the Phase 3 trial result “historic.” ABMedia also said the move lifted shares of BioNTech, AbbVie, Amgen, Eli Lilly and Johnson & Johnson. The outlet added that Moderna’s latest progress came after weaker COVID-19 vaccine demand had left investors watching its transition strategy closely, while recent sector rotation had started bringing capital back into healthcare and biotech stocks.1540
